Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease	Astellas Pharma Global Development Inc	Ongoing	roxadustat	3	1517-CL-1003	King Faisal Specialist Hospital and Research Center (Riyadh)
A multicenter real-world evidence study with retrospective chart review and cross-sectional survey to evaluate the satisfaction and benefits of long-term repeated BOTOX treatment for upper facial lines	AbbVie	Ongoing	Botox	4	H24-500	Derma Clinic
Phase II, Prospective, Randomized, placebo-controlled, double-blind study.Evaluation of Phytochemical properties and Phytotherapeutic Potential of Boswellia carteri Birdw. in Psoriasis	PI Initiated	Ongoing	boswellia carteri (Psorelia)	2	E-23-7585	King Khalid University Hospital (Riyadh)
A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure	AstraZeneca	Ongoing	Baxdrostat	3	D6972C00003	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)	Gossamer Bio	Ongoing	Seralutinib	3	GB002-3101	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials	Novartis	Ongoing	OAV101 (formerly AVXS-101)	3	COAV101A12308	King Faisal Specialist Hospital and Research Center (Riyadh)
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours	Boehringer Ingelheim Middle East & North Africa (Scientific Office) FZ Limited	Ongoing	BI 907828/ brigimadlin	2	1403-0011	King Abdulaziz Medical City NG (Riyadh)
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study	King Abdullah International Medical Research Center (KAIMRC)	Rejected	BRENTUXIMAB VEDOTIN	3	RJ19/119/J	King Abdulaziz Medical City NG (Riyadh)
Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide	Janssen-Cilag International NV	Ongoing	Talquetamab	3	80202135EBF3001	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
The effect of novel D3 use as a mouthwash in COVID-19 patients	King Faisal Specialist Hospital & Research Centre Jeddah, Saudi Arabia	Ongoing	Cholecalciferol (vitamin D)	3	2022-32	King Faisal Specialist Hospital and Research Center (Jeddah)